• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

byConstance Wu
January 29, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Ovarian cancer screening does not reduce mortality [Classics Series]

1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy.

2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Due to the late diagnosis of advanced-stage ovarian cancer, a majority of patients experience a relapse after 10 to 18 months, even after treatment with surgery and chemotherapy. Current maintenance therapy includes the option of bevacizumab alone. Upcoming trials are exploring PARP (polyadenosine diphosphate-ribose polymerase) inhibitors which target tumors with homologous-recombination deficiency (HRD), present in about 50% of high-grade serous ovarian tumors. This randomized phase 3 trial of olaparib, a PARP inhibitor, explored the effects of olaparib plus bevacizumab on progression-free survival. Participants with newly diagnosed, advanced, high-grade ovarian cancer were assigned in a 2:1 ratio to either receive olaparib at a dose of 300mg twice daily) or placebo between 3 to 9 weeks after the last chemotherapy.. Olaparib plus bevacizumab had an overall median progression-free survival of 22.1 months, as compared to 16.6 months with placebo plus bevacizumab. Disease progression and death rates were lower for those with BRCA-positive and HRD-positive tumors. Olaparib plus bevacizumab offered increased survival and decrease in relapse, especially in those with BRCA-positive and HRD-positive tumors. Future research should focus on determining long-term effects of this drug combination.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bevacizumab (Avastin)brcahomologous-recombination deficiency (HRD)Olaparibovarian cancerPARP (polyadenosine diphosphate-ribose polymerase) inhibitors
Previous Post

Decreased Frontal White-Matter Diffusion and Improved Cognitive Flexibility After Burr-Hole Surgery In Moyamoya Angiopathy

Next Post

Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

RelatedReports

Oncology

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

January 16, 2023
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Obstetrics and Gynecology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

September 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Ovarian cancer screening does not reduce mortality [Classics Series]

August 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

August 10, 2022
Next Post
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

#VisualAbstract: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

#VisualAbstract: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Medical vaccine exemptions increase after elimination of nonmedical exemptions

4CMenB vaccine ineffective in reducing carriage prevalence of disease-causing meningococci

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Symptom and viral relapse more common in COVID-19 patients without antiviral treatment
  • The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns
  • Post-traumatic stress disorder and sleep disorders may exhibit a bi-directional relationship in U.S military members
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options